Deal Flow Alert ⚡ Corstasis VP Hire

🚀 Battle Card: Corstasis Therapeutics Inc.

• Amin M. Medjamia M.D., Vice President of Medical Affairs · 🔗 LinkedIn

• Seasoned clinical affairs leader joins as company advances Enbumyst™ toward pivotal PDUFA date → Source

• Timing your pitch to this Corstasis Therapeutics Inc. sales trigger ensures alignment with their clinical roadmap

• High regulatory scrutiny for novel outpatient nasal therapies

• Urgent need to scale evidence generation for FDA submission

• Primary: Clinical trial management platform → Streamlined evidence generation & regulatory compliance

• Expansion: Medical communications service → Enhanced stakeholder engagement & clinical algorithm support

• HQ: Henderson, NV

• Employees: ≈ 100

• Rev: ≈ $20 M

• Website: https://www.corstasis.com

🤼 Competitive Intel

• Veeva Systems — Clinical Data Management / CTMS
• Unique edge: Unified clinical, regulatory & medical platform
• Selected by VP Medical Affairs for data integration

• Medidata (Dassault Systèmes) — Clinical Trial Management
• Unique edge: AI-driven trial optimization
• Evaluated by clinical ops for advanced analytics

• Parexel — Medical Affairs & Regulatory Consulting
• Unique edge: End-to-end evidence generation services
• Chosen by former VP Ops for FDA submission success

• ICON plc — Contract Research Organization
• Unique edge: Global trial execution & medical engagement
• Considered by Medical Affairs for scale & expertise

✅ Do-Now Checklist

Next Step

🧠 Copy My Prompt for Personalized Cold Outreach

────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY   = ❑❑
OFFER_BRIEF   = ❑Clinical trial management platform❑
PROOF_METRIC  = ❑25% faster trial startup❑
CTA_STYLE     = ❑quick_call❑
TONE          = ❑friendly❑

────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME        = Amin
COMPANY     = Corstasis Therapeutics Inc.
DEPT        = Medical Affairs
SIZE        = ≈ TBD
BOTTLENECK  = ≈ TBD
EVENT       = Appointment of Dr. Amin Medjamia as VP of Medical Affairs
DETAIL      = Appointment of Dr. Amin Medjamia as VP of Medical Affairs
PAIN        = High regulatory scrutiny for novel outpatient nasal therapies
SRC         = http://cts.businesswire.com/ct/CT?id=ftfLlWd9aZbF2NXfwppam3Bd664=&newsLang=en&newsId=20250911973833&div=41152219
SIM_CO      = ≈ TBD
WIN_METRIC  = ≈ TBD
NEXT_SIZE   = ≈ TBD
EMP_EST     = ≈ 100
REV_EST     = ≈ $20M

────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.

Validate any ≈ guesses via SRC.

EMAIL  (keep breaks):
Subject: ≈ TBD-person Medical Affairs

Amin—noticed your Medical Affairs team is ≈ TBD.

That’s when ≈ TBD slows growth.

We helped ≈ TBD fix this with Clinical trial management platform.

Result: ≈ TBD.  
Quick call?

PS—next bottleneck hits ≈ TBD.

DM ≤45 words, TONE:
Saw your post about Appointment of Dr. Amin Medjamia as VP of Medical Affairs — High regulatory scrutiny for novel outpatient nasal therapies.  
Clinical trial management platform. 25% faster trial startup.  
Quick chat?